Drug Trial Radar · NCT03387852
Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants
Last checked: Nov 19, 2026Latest source record: Jun 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
296
Actual
Start
Mar 12, 2018
Primary completion
Mar 21, 2019
Study completion Aug 7, 2019
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Jan 2, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To evaluate the effects of SAR440340 with or without dupilumab, compared to placebo, on reducing the incidence of "loss of asthma control" (LOAC) events. Secondary Objectives: To evaluate the effects of SAR440340/REGN3500 and coadministration of SAR440340 and dupilumab, compared with placebo, on forced expiratory volume in 1 second (FEV1). To evaluate the effects of coadministration of SAR440340 and dupilumab, compared with SAR440340 and compared with dupilumab, on FEV1. To assess safety and tolerability of SAR440340 alone and in coadministration with dupilumab.
Conditions
- Asthma
Interventions
SAR440340Drug
Pharmaceutical form: Solution for Injection, Route of administration: SC
DupilumabDrug
Pharmaceutical form: Solution for Injection, Route of administration: SC
Fluticasone or Fluticasone/salmeterol combinationDrug
Pharmaceutical form: Aerosol, dry powder, Route of administration: Inhaled
Placebo for SAR440340Drug
Pharmaceutical form: Solution for Injection, Route of administration: SC
Placebo for dupilumabDrug
Pharmaceutical form: Solution for Injection, Route of administration: SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Loss of Asthma ControlTime frame: From Baseline up to Week 12
Locations
71 sites in 8 countries. Site status is shown where the registry gives one.
Investigational Site Number 8400026
Birmingham, Alabama
Investigational Site Number 8400004
Long Beach, California
Investigational Site Number 8400020
Los Angeles, California
Investigational Site Number 8400001
Rolling Hills Estates, California
Investigational Site Number 8400013
San Jose, California
Investigational Site Number 8400009
Stockton, California
Investigational Site Number 8400016
Colorado Springs, Colorado
Investigational Site Number 8400021
Ann Arbor, Michigan
Investigational Site Number 8400022
Minneapolis, Minnesota
Investigational Site Number 8400007
Papillion, Nebraska
Investigational Site Number 8400025
Edmond, Oklahoma
Investigational Site Number 8400011
Medford, Oregon
Investigational Site Number 8400024
Portland, Oregon
Investigational Site Number 8400010
Dallas, Texas
Investigational Site Number 8400023
Dallas, Texas
Investigational Site Number 8400006
Plano, Texas
Investigational Site Number 8400008
Murray, Utah
Investigational Site Number 8400014
Milwaukee, Wisconsin
Investigational Site Number 0320001
Buenos Aires, Argentina
Investigational Site Number 0320003
Caba, Argentina
Investigational Site Number 0320002
Caba, Argentina
Investigational Site Number 0320004
Caba, Argentina
Investigational Site Number 0320005
Mendoza, Argentina
Investigational Site Number 1520002
Quillota, Chile
Investigational Site Number 1520001
Santiago, Chile
Investigational Site Number 1520009
Santiago, Chile
Investigational Site Number 1520008
Santiago, Chile
Investigational Site Number 1520007
Santiago, Chile
Investigational Site Number 1520004
Santiago, Chile
Investigational Site Number 1520005
Talca, Chile
Investigational Site Number 1520003
Viña del Mar, Chile
Investigational Site Number 4840005
Chihuahua City, Mexico
Investigational Site Number 4840004
Durango, Mexico
Investigational Site Number 4840002
Guadalajara, Mexico
Investigational Site Number 4840006
Monterrey, Mexico
Investigational Site Number 4840001
Monterrey, Mexico
Investigational Site Number 4840003
Veracruz, Mexico
Investigational Site Number 6160001
Bialystok, Poland
Investigational Site Number 6160008
Bialystok, Poland
Investigational Site Number 6160005
Bydgoszcz, Poland
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.